Skip to main content
Top
Published in: Health Research Policy and Systems 1/2015

Open Access 01-12-2016 | Study Protocol

Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project

Authors: Karen Berg Brigham, Meryl Darlington, John S. F. Wright, Grant Lewison, Panos Kanavos, Isabelle Durand-Zaleski, On behalf of the Mapping_NCD consortium

Published in: Health Research Policy and Systems | Issue 1/2015

Login to get access

Abstract

Background

Mental health disorders (MHDs) constitute a large and growing disease burden in Europe, although they typically receive less attention and research funding than other non-communicable diseases (NCDs). This study protocol describes a methodology for the mapping of MHD research in Europe as part of Mapping_NCD, a 2-year project funded by the European Commission which seeks to map European research funding and impact for five NCDs in order to identify potential gaps, overlaps, synergies and opportunities, and to develop evidence-based policies for future research.

Methods

The project aims to develop a multi-focal view of the MHD research landscape across the 28 European Union Member States, plus Iceland, Norway and Switzerland, through a survey of European funding entities, analysis of research initiatives undertaken in the public, voluntary/not-for-profit and commercial sectors, and expert interviews to contextualize the gathered data. The impact of MHD research will be explored using bibliometric analyses of scientific publications, clinical guidelines and newspaper stories reporting on research initiatives. Finally, these research inputs and outputs will be considered in light of various metrics that have been proposed to inform priorities for the allocation of research funds, including burden of disease, treatment gaps and cost of illness.

Discussion

Given the growing burden of MHDs, a clear and broad view of the current state of MHD research is needed to ensure that limited resources are directed to evidence-based priority areas. MHDs pose a particular challenge in mapping the research landscape due to their complex nature, high co-morbidity and varying diagnostic criteria. Undertaking such an effort across 31 countries is further challenged by differences in data collection, healthcare systems, reimbursement rates and clinical practices, as well as cultural and socioeconomic diversity. Using multiple methods to explore the spectrum of MHD research funding activity across Europe, this project aims to develop a broad, high-level perspective to inform priority setting for future research.
Literature
1.
go back to reference Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2013;2015(386):743–800. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2013;2015(386):743–800.
2.
go back to reference Penfield T, Baker MJ, Scoble R, Wykes MC. Assessment, evaluations, and definitions of research impact: a review. Res Eval. 2014;23:21–32.CrossRef Penfield T, Baker MJ, Scoble R, Wykes MC. Assessment, evaluations, and definitions of research impact: a review. Res Eval. 2014;23:21–32.CrossRef
3.
go back to reference Galsworthy M, Irwin R, Charlesworth K, Ernst K, Hristovski D, Wismar M, et al. An analysis of subject areas and country participation for all health-related projects in the EU’s FP5 and FP6 programmes. Eur J Pub Health. 2013;24:514–20.CrossRef Galsworthy M, Irwin R, Charlesworth K, Ernst K, Hristovski D, Wismar M, et al. An analysis of subject areas and country participation for all health-related projects in the EU’s FP5 and FP6 programmes. Eur J Pub Health. 2013;24:514–20.CrossRef
4.
go back to reference Packer C, Simpson S, de Almeida RT. EUROSCAN International Network Member Agencies: their structure, processes, and outputs. Int J Technol Assess Health Care. 2015;31:78–85.CrossRefPubMedPubMedCentral Packer C, Simpson S, de Almeida RT. EUROSCAN International Network Member Agencies: their structure, processes, and outputs. Int J Technol Assess Health Care. 2015;31:78–85.CrossRefPubMedPubMedCentral
5.
go back to reference Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.CrossRefPubMedPubMedCentral Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.CrossRefPubMedPubMedCentral
6.
go back to reference Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510–20.CrossRefPubMedPubMedCentral Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104:510–20.CrossRefPubMedPubMedCentral
7.
go back to reference Buxton M, Hanney S, Morris S, Sundmacher L, Mestre-Ferrandiz J, Garau M, Sussex J, Grant J, Ismail S, Nason E, Wooding S, Kapur S. Medical Research: What’s It Worth? : Estimating the Economic Benefits from Medical Research in the UK. London: UK Evaluation Forum; 2008. Buxton M, Hanney S, Morris S, Sundmacher L, Mestre-Ferrandiz J, Garau M, Sussex J, Grant J, Ismail S, Nason E, Wooding S, Kapur S. Medical Research: What’s It Worth? : Estimating the Economic Benefits from Medical Research in the UK. London: UK Evaluation Forum; 2008.
8.
go back to reference Hallin DC, Brandt M, Briggs CL. Biomedicalization and the public sphere: newspaper coverage of health and medicine, 1960s-2000s. Soc Sci Med 1982. 2013;96:121–8. Hallin DC, Brandt M, Briggs CL. Biomedicalization and the public sphere: newspaper coverage of health and medicine, 1960s-2000s. Soc Sci Med 1982. 2013;96:121–8.
9.
go back to reference Kinge J, Roxrud I, Vollset S, Skirbekk V, Røttingen J-A. Are the Norwegian health research investments in line with the disease burden? Health Res Policy Syst. 2014;12:64.CrossRefPubMedPubMedCentral Kinge J, Roxrud I, Vollset S, Skirbekk V, Røttingen J-A. Are the Norwegian health research investments in line with the disease burden? Health Res Policy Syst. 2014;12:64.CrossRefPubMedPubMedCentral
10.
go back to reference Polinder S, Haagsma JA, Stein C, Havelaar AH. Systematic review of general burden of disease studies using disability-adjusted life years. Popul Health Metr. 2012;10:21.CrossRefPubMedPubMedCentral Polinder S, Haagsma JA, Stein C, Havelaar AH. Systematic review of general burden of disease studies using disability-adjusted life years. Popul Health Metr. 2012;10:21.CrossRefPubMedPubMedCentral
13.
go back to reference Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ. 1997;16:685–702.CrossRefPubMed Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ. 1997;16:685–702.CrossRefPubMed
14.
go back to reference Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82:858–66.PubMedPubMedCentral Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82:858–66.PubMedPubMedCentral
15.
go back to reference Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12 Suppl 1:1–27.CrossRefPubMed Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12 Suppl 1:1–27.CrossRefPubMed
16.
go back to reference Olesen J, Gustavsson A, Svensson M, Wittchen H-U, Jönsson B, on behalf of the CDBE2010 study group, the European Brain Council. The economic cost of brain disorders in Europe: economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–62.CrossRefPubMed Olesen J, Gustavsson A, Svensson M, Wittchen H-U, Jönsson B, on behalf of the CDBE2010 study group, the European Brain Council. The economic cost of brain disorders in Europe: economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155–62.CrossRefPubMed
17.
go back to reference Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15:357–76.CrossRefPubMed Wittchen H-U, Jacobi F. Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15:357–76.CrossRefPubMed
18.
go back to reference Knapp M, Funk M, Curran C, Prince M, Grigg M, McDaid D. Economic barriers to better mental health practice and policy. Health Policy Plan. 2006;21:157–70.CrossRefPubMed Knapp M, Funk M, Curran C, Prince M, Grigg M, McDaid D. Economic barriers to better mental health practice and policy. Health Policy Plan. 2006;21:157–70.CrossRefPubMed
Metadata
Title
Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project
Authors
Karen Berg Brigham
Meryl Darlington
John S. F. Wright
Grant Lewison
Panos Kanavos
Isabelle Durand-Zaleski
On behalf of the Mapping_NCD consortium
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Health Research Policy and Systems / Issue 1/2015
Electronic ISSN: 1478-4505
DOI
https://doi.org/10.1186/s12961-016-0111-6

Other articles of this Issue 1/2015

Health Research Policy and Systems 1/2015 Go to the issue